Location of polyglutamine track affects pathogenic threshold of polyglutamine expansion diseases - Importance of association with the proteasome

Biochem Biophys Res Commun. 2024 Dec 20:745:151226. doi: 10.1016/j.bbrc.2024.151226. Online ahead of print.

Abstract

The expansion of glutamine residue track (polyQ) within soluble proteins (Q proteins) is responsible for nine autosomal-dominant genetic neurodegenerative disorders. These disorders develop when polyQ expansion exceeds a specific pathogenic threshold (Qth) which is unique for each disease. However, the pathogenic mechanisms associated with the variability of Qth within the family of Q proteins are poorly understood. In the previous publication we proposed that polarity of the regions flanking polyQ track in each protein plays a key role in defining Qth value (Kim, M. Mol Neurodegener 9 (2014) 45) and that these effects can be explained as a result of interactions between polyQ-expanded protein and proteasome (Kim, M Bezprozvanny, I (2021). Biochem Biophys Res Commun 536:95-99). In the present manuscript we extended our analysis and analyzed effects of location of polyQ-expanded track within the protein sequence. To accomplish this, we divided a family of polyQ-expanded proteins into 3 classes - G1, G2 and G3 groups, which differ by position of polyQ-expanded track in the protein sequence. We determined that polarity of flanking regions have different effect on Qth. value for each of these classes, and explained these differences by mechanistic analysis of proteasomal function. Our results further support the hypothesis that differences in Qth. values of pathogenic threshold can be explained by different mode of interactions between polyQ-flanking regions and proteasome and these findings provide novel insight into pathogenic mechanisms of polyQ-expanded disorders.

Keywords: Ataxin; Dentatorubral-pallidoluysian atrophy; Huntingtin; Huntington's disease; Intrinsically disordered protein; Polyglutamine disorders; Polyglutamine-expansion disease family; Proteasome dysfunction; SCA; Spinal and bulbar muscular atrophy; Spinocerebellar ataxia; Ubiquitination; polyQ.